Kotloff R M, Ahya V N
Pulmonary, Allergy, and Critical Care Division, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA.
Eur Respir J. 2004 Feb;23(2):334-42. doi: 10.1183/09031936.03.00043403.
Surgical advances, in conjunction with more effective immunosuppressive strategies, have propelled the field of lung transplantation forward and have made intermediate-term survival an achievable goal. Nonetheless, the post-transplant course is often marked by complications that threaten both the quality and duration of the recipient's life. Many of the medical complications that arise are the direct consequence of the need to administer potent immunosuppressive agents, with their attendant risks of infection, malignancy and drug toxicity. This article will review the major medical complications, excluding allograft rejection, which may be encountered in the lung transplant recipient. Familiarity with, and vigilance for, these problems should facilitate earlier recognition, more expeditious intervention and more favourable outcomes.
外科手术的进步,再加上更有效的免疫抑制策略,推动了肺移植领域的发展,并使中期存活成为一个可以实现的目标。尽管如此,移植后的病程往往以各种并发症为特征,这些并发症威胁着受者的生活质量和寿命。出现的许多医学并发症是需要使用强效免疫抑制剂的直接后果,随之而来的是感染、恶性肿瘤和药物毒性风险。本文将回顾肺移植受者可能遇到的主要医学并发症,不包括同种异体移植排斥反应。熟悉并警惕这些问题应有助于更早识别、更迅速干预并取得更有利的结果。